ArticleBioactive materials2022
Upconversion nanoparticles regulated drug & gas dual-effective nanoplatform for the targeting cooperated therapy of thrombus and anticoagulation.
Article in Bioactive materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Near-Infrared Light-Driven Microgrooved UCNPs/Azobenzene-LCE Actuators and Substrates for Cardiomyoblast Alignment.ACS applied materials & interfaces · 2026Article
- Magnetic/photothermal dual-driven micro/nanorobots for synergistic NO-mediated photothermal thrombolysis.Materials today. Bio · 2026Article
- A 'frost formation'-inspired near-infrared-responsive nitric oxide-releasing hydrogel for enhancing fat graft survival.Regenerative biomaterials · 2026Article
- Bacteria-Targeted Single-Atom Nanozyme With Photothermal-Augmented Multi-Enzymatic Cascade and NO Delivery for Enhanced Infected Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Programmable MRI contrast switching for spatiotemporal mapping of thrombus maturation via enzyme-directed nanoprobe reconfiguration.Nano convergence · 2025Article
- Thrombolytic therapy of human black hair and Au drug-loaded nanocapsules in vivo and in vitro based on near infrared II laser response.Journal of materials science. Materials in medicine · 2025Article
- Mechanical Biomimetic Nanocomposites for Multidimensional Treatment of Arterial Thrombosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Ultrasound-responsive nanoparticles for nitric oxide release to inhibit the growth of breast cancer.Cancer cell international · 2024Article
- "Three birds, one stone" strategy of NIR-responsive CO/HMaterials today. Bio · 2024Article
- pH-Responsive Theranostic Colloidosome Drug Carriers Enable Real-Time Imaging of Targeted Thrombolytic Process with Near-Infrared-II for Deep Venous Thrombosis.Research (Washington, D.C.) · 2024Article
- Multifunctional mesoporous silica nanoparticles for biomedical applications.Signal transduction and targeted therapy · 2023Review
- Photoswitchable upconversion nanoparticles with excitation-dependent emission for programmed stepwise NIR phototherapy.iScience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thromboembolism is the leading cause of cardiovascular mortality. Currently, for the lack of targeting, short half-life, low bioavailability and high bleeding risk of the classical thrombolytic drugs, pharmacological thrombolysis is usually a slow process based on micro-pumping. In addition, frequently monitoring and regulating coagulation functions are also required during (and after) the process of thrombolysis. To address these issues, a targeted thrombolytic and anticoagulation nanoplatform (UCATS-UK) is developed based on upconversion nanoparticles (UCNPs) that can convert 808 or 980 nm near-infrared (NIR) light into UV/blue light. This nanoplatform can target and enrich in the thrombus site. Synergistic thrombolysis and anticoagulation therapy thus could be realized through the controlled release of urokinase (UK) and nitric oxide (NO). Both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.